1stOncology™: Cancer Intelligence Service – Page 10073 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Invitae to Present at The Cowen 41st Annual Healthcare Conference

On February 22, 2021 Invitae Corporation (NYSE: NVTA), a leading medical genetics company, reported that members of its management team will present at The Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 2:50 p.m. Eastern /11:50 a.m. Pacific (Press release, Invitae, FEB 22, 2021, View Source [SID1234575377]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

The live webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the fireside chat.

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

On February 22, 2021 Genmab A/S (Nasdaq: GMAB) reported that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021 (Press release, Genmab, FEB 22, 2021, View Source [SID1234575376]). Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Operating Officer Anthony Mancini.

Based in Genmab’s New Jersey, U.S. office, Dr. Ahmadi has been instrumental in the scale up of the fully integrated R&D enterprise within Genmab, and he will serve the key role of Chief Medical Officer as Genmab continues its journey towards a leading fully integrated biotech innovation powerhouse. Before joining Genmab, Dr. Ahmadi was head of experimental medicine and early development oncology at Janssen, where he led the global development of daratumumab including clinical R&D and medical affairs strategy. A hematologist/oncologist by training, he holds an M.D. from the University of Cologne and a Ph.D. in immunology from the University of Freiburg.

"As we continue to evolve and grow our organization, I am delighted that Tahi will take on this exciting new role and further strengthen Genmab’s very strong Executive Management Team. Given his proven track record of drug development leadership and innovative thinking, I am confident that Tahi will effectively drive our R&D teams alongside Judith to deliver on our promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab."

Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

On February 22, 2021 Five Prime Therapeutics, Inc. (NASDAQ: FPRX) reported that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the virtual SVB Leerink 10TH Annual Global Healthcare Conference on Thursday, February 25, 2021 at 10:00 a.m. ET / 7:00 a.m. PT (Press release, Five Prime Therapeutics, FEB 22, 2021, View Source [SID1234575375]).

Live audio webcast of the presentation will be accessible and available for replay from the "Events & Presentations" section of the Company’s website at: View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

On February 22, 2021 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, reported that the Company will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST (Press release, Fate Therapeutics, FEB 22, 2021, View Source [SID1234575374]).

The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

Exact Sciences to participate in March investor conferences

On February 22, 2021 Exact Sciences Corp. (Nasdaq: EXAS) reported that company management will participate in the following virtual conferences and invited investors to participate by webcast (Press release, Exact Sciences, FEB 22, 2021, View Source [SID1234575373]).

Cowen 41st Annual Health Care Conference
Fireside Chat on Tuesday, March 2, 2021 at 11:50 a.m. EST

Barclays Global Healthcare Conference
Fireside Chat on Tuesday, March 9, 2021 at 9:10 a.m. EST
The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.